Pharmaceutical giants of 2026: The most prominent pharmaceutical companies in the world's Top 10

2025 was a defining year. Sixteen of the world's top 20 pharma companies achieved revenue growth. AI spending in pharma hit €2.76 billion. And 2026 opened with a wave of major AI platform deals across the industry. So, which companies are leading the charge? Let's take a closer look at the world's top 10 pharmaceutical giants and the breakthroughs they are bringing to market.

Pharmaceutical companies play a pivotal role in addressing the world's leading causes of death, including heart disease, cancer, stroke, respiratory illness, Alzheimer's, and diabetes. But their impact goes well beyond treatment. These companies are advancing precision medicine, AI-assisted drug discovery, and next-generation biologics, transforming how healthcare is delivered and how fast new therapies reach patients.

Let's take a closer look at the top 10 pharmaceutical companies in the world in 2026:

With full-year 2025 revenue of €86.9 billion, up 6.0% versus 2024, J&J remains one of the largest pharmaceutical players globally. Its Innovative Medicine division exceeded €55.6 billion in full-year pharmaceutical sales for the first time, with 13 brands growing double digits. Its oncology portfolio, led by Darzalex, continues to drive strong growth, with 21% operational growth in oncology. In January 2026, J&J entered a multi-target AI research partnership with Isomorphic Labs, Google DeepMind's drug discovery spinout. The company has issued 2026 revenue guidance with a midpoint of approximately €92.2 billion a further 6.2% growth. Headquartered in New Jersey and founded in 1886, J&J employs over 150,000 people.

The standout performer of 2025, Eli Lilly, posted full-year revenue of €60.1 billion, a 45% increase year-on-year, driven by its GLP-1 portfolio, Mounjaro and Zepbound. For 2026, Lilly has guided revenue of €73.8 billion to €76.6 billion, representing a further 23–27% growth. Lilly's manufacturing investment programme includes facilities in Houston and Virginia, as well as a €923 million AI co-innovation lab with NVIDIA for molecular simulation. In early 2026, Lilly also partnered with AI platform Chai Discovery for biologics design. Lilly employs over 43,000 people globally.

Merck delivered full-year 2025 revenue of approximately €59.9 billion, broadly flat year-on-year, as Keytruda the world's best-selling drug continued to anchor growth at approximately €27.2 billion in sales. With Keytruda's patent expiring in 2028, Merck is actively building its next pipeline wave through acquisitions, including Verona Pharma (€9.2 billion) and AI collaborations with Absci for oncology and immunology. The company has guided 2026 revenue growth of approximately 1.9%. Headquartered in New Jersey, Merck employs over 69,000 professionals.

With full-year 2025 revenue of €57.7 billion, a 2% decline as COVID-19 product revenues normalised, Pfizer is rebuilding its growth engine around oncology. Its €39.7 billion acquisition of Seagen doubled its oncology pipeline to 60 programmes and added four approved antibody-drug conjugate drugs. In early 2026, Pfizer partnered with the AI platform Boltz for small-molecule drug discovery. The company estimates AI tools are saving its scientists 16,000 hours of work annually. Pfizer has guided 2026 revenue of €54.9 billion to €57.7 billion. Headquartered in Connecticut, Pfizer employs over 80,000 people.

AbbVie delivered full-year 2025 revenue of €56.4 billion, up 8.6% year-on-year, its strongest annual growth since the Humira biosimilar transition began. Growth was driven by Skyrizi and Rinvoq, which together generated €25.8 billion in sales in 2025. AbbVie has guided 2026 revenue to approximately €61.7 billion, representing 9.5% growth, supported by projected combined Skyrizi and Rinvoq sales of over €28.6 billion. Its internal AI platform, ARCH, launched in 2024, connects over 2 billion data points across 200 data sources, and the company claims it could halve drug development timelines. AbbVie employs more than 50,000 people across 70 countries.

Roche reported full-year 2025 revenues of CHF 61.5 billion (approximately €64.6 billion), up 7% at constant exchange rates, a meaningful acceleration from 2024. The pharmaceutical division was the primary driver, growing 9% at CER to CHF 47.7 billion (approximately €50.1 billion), led by Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo. Core operating profit grew 13% at CER. The company tops the Statista AI readiness index among global pharma, with its NAVIFY platform integrating more than 20 AI algorithms and its Flatiron Health subsidiary leading in real-world oncology evidence. Headquartered in Basel, Switzerland, Roche employs more than 100,000 specialists.

Swiss-based Novartis delivered full-year 2025 net sales of approximately €50.3 billion, up 8% year-on-year, driven by the rapid scaling of newer medicines across oncology, radioligand therapy, and cardiovascular disease. Core operating income reached approximately €20.2 billion, with a core operating income margin of 40.1%. Leading in gene therapy and radioligand programmes, Novartis has entered a €2.77 billion partnership with Isomorphic Labs for AlphaFold-based drug discovery, with AI-designed molecules expected to enter Phase I trials by late 2026. The company employs more than 100,000 people globally.

AstraZeneca delivered full-year 2025 total revenue of approximately €54.2 billion, up 8% at constant exchange rates, one of the strongest performances among large pharma globally. The company announced 16 positive Phase III study readouts and 43 regulatory approvals across major regions during 2025, and now has 16 blockbuster medicines. It is jointly ranked first in the CNS Summit Pharma Innovation Index for digital transformation, has trained 12,000 employees in generative AI, and operates its Evinova GxP-validated digital clinical trial platform. AstraZeneca has guided mid-to-high single-digit revenue growth in 2026, with more than 20 Phase III trial readouts planned for the year. AstraZeneca employs over 90,000 people globally.

Sanofi reported full-year 2025 net sales of €43.6 billion, up 6.2% on a reported basis and up 9.9% at constant exchange rates, its strongest annual growth in recent years. Growth was led by Dupixent, which reached approximately €16.3 billion in full-year sales, up 32% in Q4 alone. The company has positioned itself as "the first AI-powered biopharma company operating at scale," launching its third Digital Accelerator in Lyon in 2025. Its CodonBERT AI tool cuts mRNA design time by 50%. Sanofi has guided high single-digit sales growth at CER for 2026. Sanofi employs over 91,000 people across 90 countries.

UK-based GSK delivered full-year 2025 revenues of approximately €39.1 billion, up 7% at constant exchange rates, driven by double-digit growth in Speciality Medicines across respiratory, immunology and inflammation, oncology, and HIV. Now fully focused on biopharma following the completion of the Haleon divestment, GSK partnered with AI platform Noetik in early 2026 to predict cancer clinical outcomes. GSK has confirmed 2026 guidance of 3–5% turnover growth and 7–9% core operating profit growth. The company employs around 70,000 professionals.

If 2025 was the year of AI breakthrough in pharma, 2026 is the year of deployment. Eli Lilly's €923 million NVIDIA lab, Novartis's €2.77 billion Isomorphic Labs deal, AstraZeneca's 12,000 AI-trained employees and 43 regulatory approvals in 2025, Pfizer's 16,000 hours of annual time savings, AbbVie's ARCH platform connecting 2 billion data points, and Sanofi's CodonBERT tool collectively signal that AI is now production infrastructure, not a pilot. Every organisation in this list has made a concrete, measurable AI commitment in the past twelve months.

Three shifts are consistent across the top 10. AI literacy is now an active screening criterion, not a preference, with companies assessing whether candidates can engage with AI outputs, validate them, and own the decisions that follow. Domain specialism is being valued higher, not lower. The scarcest profile is not someone who builds models, but someone who applies deep therapeutic or regulatory expertise to frame problems AI can solve. And hiring timelines have shortened; candidates with the right combination of GMP knowledge, regulatory literacy, and applied AI experience are not staying available for long.

Manufacturing expansion at Lilly, Novartis, AstraZeneca, and Sanofi is creating downstream demand for quality and compliance professionals across Europe. The FDA and EMA's January 2026 joint AI guiding principles, the first aligned regulatory framework for AI across the medicines lifecycle, are creating new submission requirements that existing regulatory teams were not sized to manage. And the global clinical trials market, projected to reach €42.6 billion in 2026, continues to drive demand for clinical operations and data management talent. Regulatory professionals with AI submission experience are among the most in-demand and least-supplied profiles in the European market right now.

Whether you are an experienced professional ready to contribute to breakthrough innovation or a hiring leader building the team that will deliver the next phase of growth, Panda International connects the people who shape the future of life sciences.

📞 Call us on +31 (0)20 2044 502

Or get in touch with us here.